Anti-fibrotic, anti-VEGF or radiotherapy treatments as adjuvants for pterygium excision: a systematic review and network meta-analysis

Table 4 Subgroup-analysis of recurrence for comparisons

Subgroup analysis	Comparator	Effect Sizes(95% CrI), by Treatment				Probability of being ranked most recurrence (%, 95% CI)	Rank most recurrence
Subgroup analysis	Comparator	Bevacizumab	MMC	5-FU	β-RT	Probability of being ranked most recurrence (%, 95% CI)	Rank most recurrence
Primary	Placebo	0.41 (0.21, 0.78)^*	0.08 (0.03, 0.19)^*	1.01 (0.26, 4.12)	0.10 (0.02, 0.40)^*	45.45 (0, 100)	2
	Bevacizumab	–	0.20 (0.07, 0.51)^*	2.61(0.59, 10.80)	0.23 (0.05, 1.10)	0.62 (0, 0)	3
	MMC	–	–	13.13 (3.01, 56.51)^*	1.17 (0.28, 5.38)	0 (0, 0)	5
	5-FU	–	–	–	0.01 (0.09, 0.66)^*	53.47 (0, 100)	1
	β-RT	–	–	–	–	0.47 (0, 0)	4
CA	Placebo	0.50 (0.23, 1.02)	0.23 (0.10, 0.51)^*	0.19 (0.05, 0.78)^*	0.33 (0.04, 2.31)	77.06 (0, 100)	1
	Bevacizumab	–	0.45 (0.17, 1.27)	0.39 (0.09, 1.76)	0.67 (0.08, 5.69)	4.44 (0, 0)	2
	MMC	–	–	0.87 (0.18, 3.82)	1.47 (0.17, 12.33)	0.21 (0, 0)	3
	5-FU	–	–	–	1.70 (0.15, 19.32)	2.37 (0, 0)	2
	β-RT	–	–	–	–	15.91 (0, 100)	1
BST	Placebo	0.46 (0.042, 1.16)	0.05 (0.014, 0.10)^*	2.26 (0.14, 6.11)	0.17 (0.01, 0.42)^*	46.92 (0, 100)	2
	Bevacizumab	–	0.44 (0.02, 1.13)	595.9 (0.33, 50.65)	2.22 (0.027, 3.74)	4.30 (0, 0)	3
	MMC	–	–	98.73 (3.54, 167.50)^*	4.72 (0.31, 11.60)	0.002 (0, 0)	5
	5-FU	–	–	–	0.84 (0.006, 1.003)	47.96 (0, 100)	1
	β-RT	–	–	–	–	0.81 (0, 0)	4

MMC mitomycin C, 5-FU 5-fluorouracil, β-RT beta-radiotherapy, CrI credible interval, CI confidence intervals
*p < 0.05. Effect sizes favor the above (column heading) intervention in each comparison when OR less than 1

ISSN: 1471-2415